Celldex Therapeutics (CLDX) Non-Current Debt (2010 - 2013)

Celldex Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $10.1 million for Q1 2013.

• In Q1 2013, Non-Current Debt rose 2.12% year-over-year to $10.1 million; the TTM figure through Mar 2013 stood at $10.1 million (up 2.12% YoY), while the FY2012 annual figure was $5.7 million, down 36.21% from the prior year.
• Non-Current Debt for Q1 2013 stood at $10.1 million, up from $5.7 million in the prior quarter.
• The five-year high for Non-Current Debt was $15.0 million in Q1 2011, with the low at $5.7 million in Q4 2012.
• The 4-year median for Non-Current Debt is $10.0 million (2011), against an average of $10.1 million.
• Peak annual rise in Non-Current Debt reached 38.06% in 2012, while the deepest fall reached 36.21% in 2012.
• Celldex Therapeutics' Non-Current Debt stood at $8.9 million in 2010, then gained by 1.34% to $9.0 million in 2011, then slumped by 36.21% to $5.7 million in 2012, then surged by 75.77% to $10.1 million in 2013.
• Business Quant data shows CLDX's Non-Current Debt at $10.1 million in Q1 2013, $5.7 million in Q4 2012, and $7.3 million in Q3 2012.